HongShan reports portfolio licensing and manufacturing partnerships

HongShan reported a global radioligand-therapy license between 博锐创合 and Novartis, and METiS partnerships including a signed manufacturing joint-venture agreement. Potential contingent consideration is not stored as received revenue or GP investment proceeds.